The global ophthalmic drugs market size is accounted at USD 45.35 billion in 2025 and is forecasted to hit around USD 72.38 billion by 2034, representing a CAGR of 5.30% from 2025 to 2034. The North America market size was estimated at USD 17.33 billion in 2024 and is expanding at a CAGR of 5.32% during the forecast period. The market sizing and forecasts are revenue-based (USD Million/Billion), with 2024 as the base year.
1.1. Research Objective
1.2. Scope of the Study
1.3. Definition
2.1. Research Approach
2.2. Data Sources
2.3. Assumptions & Limitations
3.1. Market Snapshot
4.1. Introduction
4.2. Market Classification and Scope
4.3. Industry Value Chain Analysis
4.3.1. Raw Material Procurement Analysis
4.3.2. Sales and Distribution Channel Analysis
4.3.3. Downstream Buyer Analysis
5.1. COVID-19 Landscape: Ophthalmic Drugs Industry Impact
5.2. COVID-19 - Impact Assessment for the Industry
5.3. COVID-19 Impact: Global Major Government Policy
5.4. Market Trends and Opportunities in the COVID-19 Landscape
6.1. Market Dynamics
6.1.1. Market Drivers
6.1.2. Market Restraints
6.1.3. Market Opportunities
6.2. Porter’s Five Forces Analysis
6.2.1. Bargaining power of suppliers
6.2.2. Bargaining power of buyers
6.2.3. Threat of substitute
6.2.4. Threat of new entrants
6.2.5. Degree of competition
7.1.1. Company Market Share/Positioning Analysis
7.1.2. Key Strategies Adopted by Players
7.1.3. Vendor Landscape
7.1.3.1. List of Suppliers
7.1.3.2. List of Buyers
8.1. Ophthalmic Drugs Market, by Disease
8.1.1. Eye Allergy
8.1.1.1. Market Revenue and Forecast
8.1.2. Eye Infection
8.1.2.1. Market Revenue and Forecast
8.1.3. Glaucoma
8.1.3.1. Market Revenue and Forecast
8.1.4. Retinal Disorders
8.1.4.1. Market Revenue and Forecast
8.1.5. Dry Eye
8.1.5.1. Market Revenue and Forecast
8.1.6. Others
8.1.6.1. Market Revenue and Forecast
9.1. Ophthalmic Drugs Market, by Drug Class
9.1.1. Anti-Allergy
9.1.1.1. Market Revenue and Forecast
9.1.2. Anti-Inflammatory
9.1.2.1. Market Revenue and Forecast
9.1.3. Antiglaucoma
9.1.3.1. Market Revenue and Forecast
9.1.4. Anti-VEGF Agents
9.1.4.1. Market Revenue and Forecast
10.1. Ophthalmic Drugs Market, by Dosage
10.1.1. Eye Solutions
10.1.1.1. Market Revenue and Forecast
10.1.2. Gels
10.1.2.1. Market Revenue and Forecast
10.1.3. Dessert
10.1.3.1. Market Revenue and Forecast
10.1.4. Eye Drops
10.1.4.1. Market Revenue and Forecast
10.1.5. Ointments
10.1.5.1. Market Revenue and Forecast
11.1. Ophthalmic Drugs Market, by Administration
11.1.1. Systematic
11.1.1.1. Market Revenue and Forecast
11.1.2. Topical
11.1.2.1. Market Revenue and Forecast
11.1.3. Local Ocular
11.1.3.1. Market Revenue and Forecast
12.1. Ophthalmic Drugs Market, by Product
12.1.1. Prescription Drugs
12.1.1.1. Market Revenue and Forecast
12.1.2. Over-the-Counter-Drugs
12.1.2.1. Market Revenue and Forecast
13.1. North America
13.1.1. Market Revenue and Forecast, by Disease
13.1.2. Market Revenue and Forecast, by Drug Class
13.1.3. Market Revenue and Forecast, by Dosage
13.1.4. Market Revenue and Forecast, by Administration
13.1.5. Market Revenue and Forecast, by Product
13.1.6. U.S.
13.1.6.1. Market Revenue and Forecast, by Disease
13.1.6.2. Market Revenue and Forecast, by Drug Class
13.1.6.3. Market Revenue and Forecast, by Dosage
13.1.6.4. Market Revenue and Forecast, by Administration
13.1.6.5. Market Revenue and Forecast, by Product
13.1.7. Rest of North America
13.1.7.1. Market Revenue and Forecast, by Disease
13.1.7.2. Market Revenue and Forecast, by Drug Class
13.1.7.3. Market Revenue and Forecast, by Dosage
13.1.7.4. Market Revenue and Forecast, by Administration
13.1.7.5. Market Revenue and Forecast, by Product
13.2. Europe
13.2.1. Market Revenue and Forecast, by Disease
13.2.2. Market Revenue and Forecast, by Drug Class
13.2.3. Market Revenue and Forecast, by Dosage
13.2.4. Market Revenue and Forecast, by Administration
13.2.5. Market Revenue and Forecast, by Product
13.2.6. UK
13.2.6.1. Market Revenue and Forecast, by Disease
13.2.6.2. Market Revenue and Forecast, by Drug Class
13.2.6.3. Market Revenue and Forecast, by Dosage
13.2.7. Market Revenue and Forecast, by Administration
13.2.8. Market Revenue and Forecast, by Product
13.2.9. Germany
13.2.9.1. Market Revenue and Forecast, by Disease
13.2.9.2. Market Revenue and Forecast, by Drug Class
13.2.9.3. Market Revenue and Forecast, by Dosage
13.2.10. Market Revenue and Forecast, by Administration
13.2.11. Market Revenue and Forecast, by Product
13.2.12. France
13.2.12.1. Market Revenue and Forecast, by Disease
13.2.12.2. Market Revenue and Forecast, by Drug Class
13.2.12.3. Market Revenue and Forecast, by Dosage
13.2.12.4. Market Revenue and Forecast, by Administration
13.2.13. Market Revenue and Forecast, by Product
13.2.14. Rest of Europe
13.2.14.1. Market Revenue and Forecast, by Disease
13.2.14.2. Market Revenue and Forecast, by Drug Class
13.2.14.3. Market Revenue and Forecast, by Dosage
13.2.14.4. Market Revenue and Forecast, by Administration
13.2.15. Market Revenue and Forecast, by Product
13.3. APAC
13.3.1. Market Revenue and Forecast, by Disease
13.3.2. Market Revenue and Forecast, by Drug Class
13.3.3. Market Revenue and Forecast, by Dosage
13.3.4. Market Revenue and Forecast, by Administration
13.3.5. Market Revenue and Forecast, by Product
13.3.6. India
13.3.6.1. Market Revenue and Forecast, by Disease
13.3.6.2. Market Revenue and Forecast, by Drug Class
13.3.6.3. Market Revenue and Forecast, by Dosage
13.3.6.4. Market Revenue and Forecast, by Administration
13.3.7. Market Revenue and Forecast, by Product
13.3.8. China
13.3.8.1. Market Revenue and Forecast, by Disease
13.3.8.2. Market Revenue and Forecast, by Drug Class
13.3.8.3. Market Revenue and Forecast, by Dosage
13.3.8.4. Market Revenue and Forecast, by Administration
13.3.9. Market Revenue and Forecast, by Product
13.3.10. Japan
13.3.10.1. Market Revenue and Forecast, by Disease
13.3.10.2. Market Revenue and Forecast, by Drug Class
13.3.10.3. Market Revenue and Forecast, by Dosage
13.3.10.4. Market Revenue and Forecast, by Administration
13.3.10.5. Market Revenue and Forecast, by Product
13.3.11. Rest of APAC
13.3.11.1. Market Revenue and Forecast, by Disease
13.3.11.2. Market Revenue and Forecast, by Drug Class
13.3.11.3. Market Revenue and Forecast, by Dosage
13.3.11.4. Market Revenue and Forecast, by Administration
13.3.11.5. Market Revenue and Forecast, by Product
13.4. MEA
13.4.1. Market Revenue and Forecast, by Disease
13.4.2. Market Revenue and Forecast, by Drug Class
13.4.3. Market Revenue and Forecast, by Dosage
13.4.4. Market Revenue and Forecast, by Administration
13.4.5. Market Revenue and Forecast, by Product
13.4.6. GCC
13.4.6.1. Market Revenue and Forecast, by Disease
13.4.6.2. Market Revenue and Forecast, by Drug Class
13.4.6.3. Market Revenue and Forecast, by Dosage
13.4.6.4. Market Revenue and Forecast, by Administration
13.4.7. Market Revenue and Forecast, by Product
13.4.8. North Africa
13.4.8.1. Market Revenue and Forecast, by Disease
13.4.8.2. Market Revenue and Forecast, by Drug Class
13.4.8.3. Market Revenue and Forecast, by Dosage
13.4.8.4. Market Revenue and Forecast, by Administration
13.4.9. Market Revenue and Forecast, by Product
13.4.10. South Africa
13.4.10.1. Market Revenue and Forecast, by Disease
13.4.10.2. Market Revenue and Forecast, by Drug Class
13.4.10.3. Market Revenue and Forecast, by Dosage
13.4.10.4. Market Revenue and Forecast, by Administration
13.4.10.5. Market Revenue and Forecast, by Product
13.4.11. Rest of MEA
13.4.11.1. Market Revenue and Forecast, by Disease
13.4.11.2. Market Revenue and Forecast, by Drug Class
13.4.11.3. Market Revenue and Forecast, by Dosage
13.4.11.4. Market Revenue and Forecast, by Administration
13.4.11.5. Market Revenue and Forecast, by Product
13.5. Latin America
13.5.1. Market Revenue and Forecast, by Disease
13.5.2. Market Revenue and Forecast, by Drug Class
13.5.3. Market Revenue and Forecast, by Dosage
13.5.4. Market Revenue and Forecast, by Administration
13.5.5. Market Revenue and Forecast, by Product
13.5.6. Brazil
13.5.6.1. Market Revenue and Forecast, by Disease
13.5.6.2. Market Revenue and Forecast, by Drug Class
13.5.6.3. Market Revenue and Forecast, by Dosage
13.5.6.4. Market Revenue and Forecast, by Administration
13.5.7. Market Revenue and Forecast, by Product
13.5.8. Rest of LATAM
13.5.8.1. Market Revenue and Forecast, by Disease
13.5.8.2. Market Revenue and Forecast, by Drug Class
13.5.8.3. Market Revenue and Forecast, by Dosage
13.5.8.4. Market Revenue and Forecast, by Administration
13.5.8.5. Market Revenue and Forecast, by Product
14.1. Johnson & Johnson services
14.1.1. Company Overview
14.1.2. Product Offerings
14.1.3. Financial Performance
14.1.4. Recent Initiatives
14.2. Novartis AG
14.2.1. Company Overview
14.2.2. Product Offerings
14.2.3. Financial Performance
14.2.4. Recent Initiatives
14.3. Bausch Health
14.3.1. Company Overview
14.3.2. Product Offerings
14.3.3. Financial Performance
14.3.4. Recent Initiatives
14.4. Santen pharmaceutical company limited
14.4.1. Company Overview
14.4.2. Product Offerings
14.4.3. Financial Performance
14.4.4. Recent Initiatives
14.5. Pfizer Inc.
14.5.1. Company Overview
14.5.2. Product Offerings
14.5.3. Financial Performance
14.5.4. Recent Initiatives
15.1. Primary Research
15.2. Secondary Research
15.3. Assumptions
16.1. About Us
16.2. Glossary of Terms
For questions or customization requests, please reach out to us at sales@precedenceresearch.com
No cookie-cutter, only authentic analysis – take the 1st step to become a Precedence Research client
Report Description
Get a Sample